Wavre

Human papillomavirus HPV infection is very common and often causes warts, which can appear at any age. This research investigates the effectiveness of two treatments, 2LVERU4 JUNIOR and 2LVERU4, compared to a placebo, in helping warts disappear. The study is placebo-controlled, randomized, and double-blind, aiming to see if these treatments improve wart clearance by the end of six months of treatment. Participants will take one capsule daily for six months, either 2LVERU4 JUNIOR or 2LVERU4, or a placebo, all taken on an empty stomach before breakfast. After the treatment phase, there is a three-month follow-up to monitor for any wart recurrence. Success is measured by normal skin color, texture, and touch at wart sites compared to the start of the study. During the study, participants will have regular assessments up to nine months from the start, including checking wart disappearance at four and six months and tracking any recurrence three months after treatment ends. Pain related to warts and safety through adverse event monitoring will also be evaluated. The study expects to enroll 162 patients aged three years and older with common, plantar, or flat warts.

Epstein-Barr Virus EBV infects most adults worldwide and can cause various diseases including infectious mononucleosis and chronic fatigue syndrome. This trial evaluates two drugs, 2LEBV and 2LXFS, to study their effects on reducing fatigue and other symptoms related to EBV infection. The study aims to provide new information on their effectiveness compared to placebo in treating EBV infections. Participants will take one capsule daily of either 2LEBV, 2LXFS, or placebo for six continuous months. Capsules are taken sequentially by number, one per day before breakfast on an empty stomach. The treatment follows a specific order from capsule 1 through 10, repeated continuously for the full treatment duration. During the study, participants will complete fatigue questionnaires called the Multidimensional Fatigue Inventory-20 MFI-20 to measure general and specific types of fatigue. Researchers will also monitor other EBV symptoms, lymphocyte typing, and safety by tracking adverse events over six to twelve months. Participation involves regular assessments through the treatment period and beyond to evaluate the drugs impact on fatigue and symptoms.